RANDOX LABORATORIES LIMITED Patent applications |
Patent application number | Title | Published |
20160097784 | DETECTION OF POLYMYXINS - The present invention relates to antibodies for use in detecting polymyxins and tracers; and to a single-capture immunodetection method and kits, each utilising the antibodies of the invention, and disclosed tracers. | 04-07-2016 |
20160084859 | DETECTION OF INDAZOLE SYNTHETIC CANNABINOIDS - Components for enabling immunodection of indazole synthetic cannabinoids are described including immunogens, haptens, antibodies, methods and kits. | 03-24-2016 |
20140287441 | IMMUNOASSAY FOR CYCLOPROPYLINDOLE BASED SYNTHETIC CANNABINOIDS, METABOLITES AND DERIVATIVES THEREOF - The invention relates to the detection and quantification of cyclopropylindole based synthetic cannabinoids UR-144 and XLR-11 by providing antibodies based on novel immunogens. These antibodies can be incorporated into methods and kits for the detection of UR-144, XLR-11 and their metabolites. | 09-25-2014 |
20140242618 | Ritalinic Acid Immunoassay - The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methyphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies. | 08-28-2014 |
20140242617 | Immunoassay for Detecting Kratom, its Constituents and their Use - The invention relates to the field of drug detection and describes antibody-based components methods and kits for the detection and quantification of alkaloids of the plant kratom. The invention is underpinned by novel antibodies which specifically bind to mitragynine alkaloids found in the kratom plant and their metabolites. | 08-28-2014 |
20140147859 | Venlafaxine Assay - The invention describes antibodies that bind venlafaxine and O-desmethylvenlafaxine. The antibodies are derived from novel haptens and immunogens and are used in methods and kits to detect and quantify venlafaxine and O-desmethylvenlafaxine. The invention also describes novel detecting agents which can be used in the methods and kits of the invention. | 05-29-2014 |
20130345581 | COMBINATION FOR EARLY EXCLUSION OF ACUTE MYOCARDIAL INFARCTION - A method for ‘ruling out’ acute myocardial infarction (AMI) in a subject presenting with chest pain expected to be cardiac in nature. The method includes a) recording an Electrocardiography (ECG) reading from said subject, b) determining the amount of Heart-type Fatty acid binding protein (H-FABP) and cardiac Troponin T (cTnT) in a sample from said subject, c) comparing the results from b) to reference values for ruling out an acute Myocardial Infarction in a subject, and d) based on the results from steps a)-c) either ‘ruling out’ or ‘ruling in’ a diagnosis of acute Myocardial Infarction in said subject. | 12-26-2013 |
20130310277 | MULTI-ANALYTE MICROARRAYS USING TAG-SPECIFIC ANTIBODIES AND TAG-ANCHORED ANTIBODIES - The invention describes accurate and flexible methods and kits for conducting multi-analyte microarrays through the use of Tag-specific antibodies and analyte-specific Tag-anchored antibodies. | 11-21-2013 |
20130224882 | Assay for the Detection of the Phenylpiperazine Family - The current invention describes novel immunogens which are used in the production of novel antibodies with unique binding properties in that they cross-react with a variety of phenylpiperazine derivatives. These antibodies enable methods and kits to detect and/or determine phenylpiperazine derivatives (for example mCPP, TFMPP and MeOPP) in an in vitro sample which are advantageous over currently available analytical methods in terms of cost, ease of use, speed and sensitivity. | 08-29-2013 |
20130210167 | IMMUNOASSAY FOR PYRROLIDINOPHENONES - The invention describes antibodies that bind molecules of the pyrrolidinophenone class of synthetic drugs. The antibodies are derived from novel chemical intermediates, haptens and immunogens and are used in methods and kits to detect and quantify pyrrolidinophenones. | 08-15-2013 |
20130196354 | Detection of Synthetic Cannabinoids - The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and RCS families. Unique antibodies derived from novel immunogens enable said methods and kits. | 08-01-2013 |
20130066053 | Detection of Synthetic Cannabinoids - The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits. | 03-14-2013 |
20130065323 | Detection of Synthetic Cannabinoids - The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the CP family. Unique antibodies derived from novel immunogens enable said methods and kits. | 03-14-2013 |
20120322089 | SENSITIVE AND GENERIC ANTIBODIES AND MULTIPLE APPLICATIONS - The invention relates to the detection and quantification of carbamazepine drugs and their metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications. | 12-20-2012 |
20120283127 | DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE - The present invention provides an ex vivo method for aiding the diagnosis of Alzheimer's disease in a patient, the method comprising the steps of determining the level of expression of at least four platelet proteins in a platelet sample from the patient selected from monoamine oxidase-B, coagulation factor Xllla, total tropomyosin (a and 13), WD-repeat protein 1 and apolipoprotein E4; and comparing the result of (i) to a control value, wherein a result higher than the control value is indicative of Alzheimer's disease. Preferably, the method of the invention further comprises determining the level of expression of wild-type GSTO-1 or mutant GSTO-1. | 11-08-2012 |
20120208213 | Detection of Synthetic Cannabinoids - The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits. | 08-16-2012 |
20120164756 | ASPIRIN ASSAY - The invention describes a method for monitoring and detecting non-therapeutic, therapeutic and toxic concentrations of aspirin in individuals which uses the urinary salicylic acid to salicyluric acid ratio. | 06-28-2012 |
20120003674 | Chloral Hydrate Detection - The invention relates to an immunoassay method and kit for the indirect detection of chloral hydrate. The invention is underpinned by a novel immunogen that produces an antibody that is specific for the chloral hydrate metabolite trichloroethanol glucuronide. Detection and quantification of trichloroethanol glucuronide has important applications in clinical toxicology, drug facilitated crime, water testing and solvent exposure. | 01-05-2012 |
20110183317 | DETERMINING THE SENSITIVITY OF A CELL TO A DRUG - The present invention provides an in vitro method for determining the resistance or sensitivity of a cell line or patient sample to a deoxyribonucleoside kinase-dependent drug, wherein the method comprises the steps of: (i) treating a patient sample or cell line, or a portion thereof, with a deoxyribonucleoside kinase-dependent drug; (ii) lysing the cells of the patient sample or cell line from step (i); (iii) optionally, mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for deoxyribonucleoside kinase; (iv) mixing a portion of the cell lysate from (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase and a deoxyribonucleoside kinase transcription promoter; (v) mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase, a deoxyribonucleoside kinase transcription promoter and a dephosphorylating agent; and (vi) measuring the bioluminescence of each of the mixtures from steps (iii) to (v), wherein the comparative levels of bioluminescence of each of the mixtures provides a measure of the resistance or sensitivity to the drug. | 07-28-2011 |